Journey Medical (NASDAQ:DERM – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Journey Medical to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Journey Medical and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Journey Medical | 2 | 0 | 2 | 0 | 2.00 |
| Journey Medical Competitors | 7845 | 13797 | 25812 | 1039 | 2.41 |
Journey Medical currently has a consensus target price of $13.00, suggesting a potential upside of 213.63%. As a group, “Pharmaceuticals” companies have a potential upside of 23.61%. Given Journey Medical’s higher possible upside, research analysts clearly believe Journey Medical is more favorable than its competitors.
Volatility & Risk
Journey Medical has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Journey Medical’s competitors have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Institutional and Insider Ownership
7.2% of Journey Medical shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Journey Medical and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Journey Medical | -7.34% | -16.07% | -5.26% |
| Journey Medical Competitors | -2,398.26% | -203.62% | -15.08% |
Earnings and Valuation
This table compares Journey Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Journey Medical | $61.86 million | -$11.43 million | -23.03 |
| Journey Medical Competitors | $18.60 billion | $3.23 billion | 560.44 |
Journey Medical’s competitors have higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Journey Medical competitors beat Journey Medical on 7 of the 13 factors compared.
Journey Medical Company Profile
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
